Información del artículo
Resumen
La determinación de BRCA 1 y 2 identifica a un grupo de pacientes con alto riesgo de cáncer de mama y ovario. Actualmente, las opciones para estas mujeres incluirían la vigilancia, quimioprevención y cirugía profiláctica. Esta situación requiere un enfoque multidisciplinario y el propósito de este estudio es analizar las diversas estrategias disponibles
Palabras Clave:
Brca
Hereditario
Cáncer de mama
Cáncer de ovario
Abstract
The availability of BRCA 1 and 2 determination identifies a patient group at high risk for breast and ovarian cancer. Currently, the therapeutic options for these women include close follow-up, chemoprevention and prophylactic surgery. This situation requires a multidisciplinary approach, so the purpose of this study is to analyze the various available strategies.
Keywords:
Brca
Hereditary
Breast cancer
Ovarian cancer
El Texto completo está disponible en PDF
Bibliografía
[1.]
H.T. Lynch, A.J. Krush.
Carcinoma of the breast and the ovary in three families.
Surg Gynecol Obstet, 133 (1971), pp. 644-648
[2.]
H.T. Lynch, R.E. Harris, H.A. Guirgis, K. Maloney, L. Carmody, J.F. Lynch.
Familiar association of breast/ovarian carcinoma.
Cancer, 41 (1978), pp. 1543-1548
[3.]
J.M. Hall, M.K. Lee, B. Newman, J.E. Morrow, L.A. Anderson, B. Huey, et al.
Linkage of early-onset familiar breast cancer to chromosome 17q21.
Science, 250 (1990), pp. 1684-1689
[4.]
Y. Miki, J. Swensen, D. Shattuck-Edens, P.A. Futreal, K. Harshman, S. Tavtigian, et al.
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA 1.
Science, 266 (1994), pp. 66-71
[5.]
R. Wooster, S.L. Neuhausen, J. Mangion, Y. Quirk, D. Ford, N. Collins, et al.
Localization of a breast cancer susceptibility gene BRCA2, to chromosome 13q12.
Science, 265 (1994), pp. 2088-2090
[6.]
R. Wooster, G. Bignell, J. Lancaster, S. Swift, S. Seal, J. Mangion, et al.
Identification of the breast cancer susceptibility gene BRCA2.
Nature, 378 (1995), pp. 789-792
[7.]
S.V. Tavtigian, J. Simard, J. Rommens, F. Couch, D. Shattuck-Eidens, S. Neuhausen, et al.
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds.
Nature Genet, 12 (1996), pp. 333-337
[8.]
J. Boyd.
BRCA: the breast, ovarian and other cancer genes.
Gynecol Oncol, 80 (2001), pp. 337-340
[9.]
Breast Cancer Trialists Collaborative Group.
Tamoxifen for early breast cancer: an overview of the randomized trials.
Lancet, 351 (1998), pp. 1451-1457
[10.]
B. Fisher, J.P. Constantino, D.L. Wickerham, C.K. Redmon, M. Kavanah, W.M. Cronin, et al.
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast Cancer and Bowel Projet P-1 Study.
J Natl Cancer Inst, 90 (1998), pp. 371-388
[11.]
T. Powles.
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital Tamoxifen Randomised Chemoprevention trial.
Lancet, 352 (1998), pp. 98-101
[12.]
U. Veronesi.
Prevention of breast cancer with tamoxifen. Preliminary findings from the Italian randomised trial among histerectomised women.
Lancet, 352 (1998), pp. 93-97
[13.]
P. Bruzzi.
Tamoxifen for prevention of breast cancer. Important questions remain unanswered, an existing trials should continue.
Bmj, 316 (1998), pp. 1181-1182
[14.]
L.S. Kinsinger, R. Harris.
Chemoprevention of breast cancer: a promising idea with an uncertain future.
Lancet, 360 (2002), pp. 813-814
[15.]
M.H. Gail, L.A. Brinton, D.P. Byar, D.K. Corle, S.B. Green, C. Schairer, et al.
Projecting individualised probabilities of developing breast cancer for white females who are being examined annually.
J Natl Cancer Inst, 81 (1989), pp. 1879-1886
[16.]
O.T. Johanson, I. Idvall, C. Anderson, A. Borg, R.B. Barkadottir, V. Egilsson, et al.
Tumor biological features of BRCA1 induced breast and ovarian cancer.
Eur J Cancer, 33 (1997), pp. 362-371
[17.]
IBIS Investigators.
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.
Lancet, 360 (2002), pp. 817-824
[18.]
S.W. Duffy, R.M. Nixon.
Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations.
Br J Cancer, 86 (2002), pp. 218-221
[19.]
S.A. Narod, J.S. Brunet, P. Ghadirian, M. Robson, K. Heimdal, S.L. Neuhausen, et al.
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutations carriers: a case control study.
Lancet, 356 (2000), pp. 1876-1881
[20.]
A. Eisen, T.R. Rebbeck, W.C. Wood, B.L. Weber.
Prophylactic surgery in women with hereditary predisposition to breast and ovarian cancer.
J Clin Oncol, 18 (2000), pp. 1980-1995
[21.]
H.F. Vasen, N.E. Haites, D.G. Evans, C.M. Steel, P. Moller, S. Hodgson, et al.
Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familiar Breast Cancer Collaborative Group.
Eur J Cancer, 34 (1998), pp. 859-860
[22.]
L. Tabar, S.W. Duffy, B. Vitak, H.H. Chen, T.C. Prevost.
The natural history of breast carcinoma. What have we learned from screening?.
Cancer, 86 (1999), pp. 449-462
[23.]
C.T.M. Brekelmans, C. Seynaeva, C.C.M. Bartels, et al.
Effectiveness of breast cancer suirveillance in BRCA1/2 gene mutation carriers and women with high familiar risk.
J Clin Oncol, 19 (2001), pp. 924-930
[24.]
M.J. Stoutjesdijk, C. Boetes, G.J. Jager, et al.
Magnetic resonance imaging in women with hereditary risk of breast cancer.
J Natl Cancer Inst, pp. 1095-1102
[25.]
P. Moller, A. Borg, D.G. Evans.
Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA, mutations and ooforectomy.
Int J Cancer, 101 (2002), pp. 555-559
[26.]
R.A. Kerber, M.L. Slattery.
The impact of family history on ovarian cancer risk: the Utah population database.
Arch Intern Med, 155 (1995), pp. 905-912
[27.]
H. Jerstrom, C. Lerman, P. Ghadirian, et al.
Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2.
Lancet, 354 (1999), pp. 1846-1850
[28.]
H. Meijers-Heijboer, B. Van Geel, W.L.J. Van Putten, S.C. Henzen-Logmans, C. Seynaeve, M.B.E. Menke-Pluymers, et al.
Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.
N Engl J Med, 345 (2001), pp. 159-164
[29.]
D.L. Brown, P.M. Doubilet, F.H. Miller, et al.
Benign and malignant ovarian masses: selection of the most discriminating gray-scale and Doppler sonographic features.
Radiology, 208 (1998), pp. 103-110
[30.]
E. Andolf, C. Jorgensen, B. Astedt.
Ultrasound examination for detection of ovarian carcinoma in risk groups.
Obstet Ginecol, 75 (1990), pp. 106-109
[31.]
I.J. Jacobs, S.J. Skates, N. McDonald, et al.
Screening for ovarian cancer: a pilot randomized controlled trial.
Lancet, 353 (1999), pp. 1207-1210
[32.]
M.G. Muto, D.W. Cramen, D.L. Brown, et al.
Screening for ovarian cancer: the preliminary experience of a familial ovarian cancer centre.
Ginecol Oncol, 51 (1993), pp. 12
[33.]
Y. Xu, Z. Shen, D.W. Wiper, et al.
Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers.
Jama, 280 (1998), pp. 719-723
[34.]
NIH Consensus Development Panel on Ovarian Cancer: screening, treatment and follow-up.
Jama, 273 (1995), pp. 491-497
[35.]
U. Menon, A. Talaat, A.N. Rosenthal, et al.
Performance of ultrasound as a second line test to serum Ca-125 in ovarian cancer screening.
Br J Obstet Gynaecol, 107 (2000), pp. 165-169
[36.]
S.A. Narod, H. Risch, R. Moslehi, A. Dorum, S. Neuhausen, H. Olsson, et al.
Oral contraceptives and risk of hereditary ovarian cancer.
N Engl J Med, 339 (1998), pp. 424-428
[37.]
H.T. Lynch, J.C. Murray.
Current status of prophylactic surgery for hereditary breast an gynecolgic cancers.
Curr Op Obstet Gynecol, 13 (2001), pp. 25-30
[38.]
N.F. Hicken.
Mastectomy: clinical pathologic study demonstrating why most mastectomies result in incomplete removal of mammary gland.
Arch Surg, 0 (1940), pp. 6-14
[39.]
L.D. Ziegler, S.S. Kroll.
Primary breast cancer after prophylactic mastectomy.
Am J Clin Oncol, 14 (1991), pp. 451-454
[40.]
S. Eldar, M.M. Meguid, J.D. Beatty.
Cancer of the breast after prophylactic subcutaneous mastectomy.
Am J Surg, 148 (1984), pp. 692-693
[41.]
J.E Goodnigtht Jr., J.M. Quagliana, D.L. Morton.
Failure of subcutaneous mastectomy to prevent the development of breast cancer.
J Surg Oncol, 26 (1984), pp. 198-201
[42.]
L.C. Hartman, D.J. Schaid, J.E. Woods, T.P. Crotty, J.L. Myers, P.D. Arnold, et al.
Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer.
N Engl J Med, 340 (1999), pp. 77-84
[43.]
A.S. Whittemore, G. Gong, J. Itnyre.
Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from Three US population-based case-control studies of ovarian cancer.
Am J Hum Genet, 60 (1997), pp. 496-504
[44.]
S. Thorlacius, S. Sigurdsson, H. Bjarnadotir, et al.
Study of a single BRCA2 mutation with high carrier frecuency in a small population.
Am J Hum Genet, 60 (1997), pp. 1079-1084
[45.]
O.T. Johansson, J. Ranstan, A. Borg, et al.
Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden.
J Clin Oncol, 16 (1998), pp. 397-404
[46.]
C.M. Phelan, J.M. Lancaster, P. Tonin, et al.
Mutation analysis of the BRCA 2 gene in 49 site-specific breast cancer families.
Nat Genet, 13 (1996), pp. 120-122
[47.]
H. Eerola, K. Aittomaki, S. Asko-Selyavaara, et al.
Hereditary breast cancer and handling of patients at risk.
Scand J Surg, 91 (2002), pp. 280-287
[48.]
T.W. Klamer, W.L. Donegann, M.H. Max.
Breast tumor incidence in rats after partial mammary resection.
Arch Surg, 118 (1983), pp. 933-935
[49.]
H. Nelson, S.H. Miller, D. Buck, et al.
Efectiveness of prophylactic mastectomy in the prevention of breast tumors in C3H mice.
Plast Reconstr Surg, 83 (1989), pp. 662-669
[50.]
D.F. Easton, D. Ford, D.T. Bishop, The Breast Cancer Linkage Consortium.
Breast and ovarian cancer incidence in BRCA1 mutation carriers.
Am J Hum Genet, 56 (1995), pp. 265-271
[51.]
G.F. Robbins, S.W. Berg.
Bilateral primary breast cancer.
Cancer, 17 (1964), pp. 1501-1527
[52.]
E.P. Mamounas, J. Bryant, B. Fisher, et al.
Primary breast cancer (PBC) as a risk factor for subsequent contralateral breast cancer (CBC): NSABP experience from the nine randomised adjuvants trials [abstract].
Breast Cancer Res Treat, 50 (1998), pp. 230
[53.]
T.S. Frank, S.A. Manley, O.I. Olopade, et al.
Sequence analysis of BRCA 1 and BRCA 2: correlation of mutations with family history and ovarian cancer risk.
J Clin Oncol, 16 (1998), pp. 2417-2425
[54.]
E. Hoffman.
The contralateral breast in ipsilateral breast carcinoma.
South Med J, pp. 151-161
[55.]
F.K. Beller, H. Nienhaus, W. Niedner, et al.
Bilateral breast cancer: the frequency of undiagnosed cancers.
Am J Obstet Gynecol, 155 (1986), pp. 247-255
[56.]
A. Ringberg, B. Palme, F. Linell.
The contralateral breast at reconstructive surgery after breast cancer operation. A histopathological study.
Breast Cancer Res Treat, 2 (1982), pp. 151-161
[57.]
L.N. Looder, P.G. Frets, R.W. Trijsburg, et al.
One year follow-up of women opting for presyntomatic testing for BRCA-1 and BRCA-2: emotional impact of the test outcome and decisions on risk management (survillance or prophylactic surgery).
Breas Cancer Res Treat, 73 (2002), pp. 97-112
[58.]
L.A. Newman, H.M. Kuerer, K.K. Hung, G. Vlastos, F.C. Ames, M.I. Ross, et al.
Prophylactic mastectomy.
J Am Coll Surg, 191 (2000), pp. 322-330
[59.]
American Cancer Society.
Cancer facts and figures–2002.
[60.]
J.P. Struewing, P. Hartge, S. Wacholder, et al.
The risk of cancer associated with specific mutations of BRCA-1 and BRCA-2 among Ashkenazi Jews.
N Engl J Med, 336 (1997), pp. 1401-1408
[61.]
H.A. Risch, J.R. Mclaughlin, D.E.C. Cole, et al.
Prevelence and penetrance of germline BRCA1 and BRCA2 mutations in populations series of 649 women with ovarian cancer.
Am J Hum Genet, 68 (2001), pp. 700-710
[62.]
S.A. Narod, J. Boyd.
Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer.
Curr Op Obstet Gynecol, 14 (2002), pp. 1926
[63.]
The Breast Cancer Linkage Consortium.
Variation in cancer risks by mutation position in BRCA2 mutation carriers.
J Nat Cancer Inst,
[64.]
M.S. Piver, M.F. Jishi, Y. Tsukada, et al.
Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer: a report of the Hilda Radner Familiar Ovarian Cancer Registry.
Cancer, 71 (1993), pp. 2751-2755
[65.]
M.S. Van Roosmalen, L.C. Verhoef, P.F. Stalmeier, N. Hoogerbrugge, W.A. Van Daal.
Decision of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role of oophorectomy.
J Clin Oncol, 20 (2002), pp. 2092-2100
[66.]
L.S. Cook, E. White, S.M. Schwartz, et al.
A population-based study of contralateral breast cancer following a primary breast cancer.
Causes Control, 7 (1996), pp. 382-390
[67.]
N. Krieger, M. Sloan, M. Cotterchio, V. Kirsh.
The risk of breast cancer following reproductive surgery.
Eur J Cancer, 35 (1999), pp. 97-101
[68.]
A. Eisen, T.R. Rebbeck, H.T. Lynch, et al.
Reduction in breast cancer risk following bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers [abstract 250].
Proceedings of Fiftieth Annual Meeting of the American Society of Human Genetics,
[69.]
W.J. Meijers, A.C. Van Lindert.
Prophylactic oophorectomy.
Eur J Obstet Gynecol Reprod Biol, 47 (1992), pp. 59-65
[70.]
F. Parazzini, C. Braga, C. La Vecchia, E. Negri, S. Acerboni, S. Franchesi.
Hysterectomy, ooforectomy and premenopause and risk of breast cancer.
Obstet Gynecol, 90 (1997), pp. 453-456
[71.]
Reebeck TR. Breast cancer risk after prophylactic oophorectomy in BRCA1 mutation carriers
[72.]
N.D. Kauff, J.M. Stagopan, M.E. Robson, L. Scheuer, M. Hensley, C.A. Huddis, et al.
Risk reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
N Engl J Med, 346 (2002), pp. 1609-1615
[73.]
K.H. Lu, J.E. Garber, D.W. Cramer, et al.
Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy.
J Clin Oncol, 18 (2000), pp. 2728-2732
[74.]
T.J. Colgan, S.L. Boerner, J. Murphy, D.E.C. Cole, S. Narod, B. Rosen.
Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy.
Ginecol Oncol, 85 (2002), pp. 397-403
[75.]
K. Leeper, R. García, E. Swisher.
Pathologic findings in prophylactic oophorectomy specimens in high-risk women.
Ginecol Oncol, 87 (2002), pp. 52-56
[76.]
K. Tiller, B. Meiser, P. Butow.
Psichological impact of prophylactic oophorectomy in women at increased risk of developing ovarian cancer: a prospective study.
Ginecol Oncol, 86 (2002), pp. 212-219
Copyright © 2003. Sociedad Española de Ginecología y Obstetricia